

Publikationsverzeichnis

Priv. Doz. Dr. med. Dr. med. habil.

Florian Eckel

Originalarbeiten

1. Roder JD, Stein HJ, **Eckel F**, Herschbach P, Henrich G, Böttcher K, Busch R, Siewert JR: Vergleich der Lebensqualität nach subtotaler und totaler Gastrektomie beim Magenkarzinom. *Dtsch Med Wochenschr* 1996; 121(17): 543–9
2. Lersch C, **Eckel F**, Sader R, Paschalidis M, Zeilhofer F, Schulte-Frohlinde E, Theiss W: Initial experience with healthport miniMax and other peripheral arm ports in patients with advanced gastrointestinal malignancy. *Oncology* 1999; 57(4): 269–75
3. Adelsberger H, Quasthoff S, Grosskretz J, Lepier A, **Eckel F**, Lersch C: The chemotherapeutic oxaliplatin alters inactivation kinetics of voltage-gated sodium channels on rat sensory neurons. *Eur J Pharmacol* 2000; 406(1): 25–32
4. Born P, Lippl F, Ulm K, Gerein P, Lersch C, **Eckel F**, Fischer G, Sandschin W, Dlaska U, Classen M: Reduced levels of coagulation factor XIII in patients with advanced tumor disease. *Hepatogastroenterol* 2000; 47(31): 194–8
5. **Eckel F**, Lersch C, Lippl F, Assmann G, Schulte-Frohlinde E: Phase II trial of cyclophosphamide, leucovorin, 5-fluorouracil 24-hour infusion and tamoxifen in pancreatic cancer. *J Exp Clin Cancer Res* 2000; 19(3): 295–300
6. Weigert N, **Eckel F**, Born P, Erhardt W, Henke J, Werner M, Classen M, Rösch T: Endohyperthermia—experimental evaluation of a new therapeutic approach for treatment of biliary carcinoma. *Endoscopy* 2000; 32(4): 306–10
7. Huber W, Jeschke B, Kreymann B, Hennig M, Page M, Salmhofer H, **Eckel F**, Schmidt U, Umgelter A, Schweigart U, Classen M: Haemodialysis for the prevention of contrast-induced nephropathy: outcome of 31 patients with severely impaired renal function, comparison with patients at similar risk and review. *Invest Radiol* 2002; 37(9): 471–81
8. **Eckel F**, Lersch C, Assmann G, Schulte-Frohlinde E: Toxicity of a 24-hour infusion of gemcitabine in biliary tract and pancreatic cancer: a pilot study. *Cancer Invest* 2002; 20(2): 180–5
9. **Eckel F**, Lersch C, Lippl F, Schulte-Frohlinde E, Schusdziarra V, Helmberger H, Neverve J, Decker M, Frank R, Schwaiger M, Weber W: Monitoring of tumor glucose metabolism by positron emission tomography in a phase I study evaluating hormonal therapy in advanced pancreatic cancer. *Scand J Gastroenterol* 2002; 37(8): 972–7
10. **Eckel F**, Schmelz R, Erdmann J, Adelsberger H, Quasthoff S, Lersch C: Prophylaxe der Oxaliplatin-induzierten Neuropathie mit Carbamazepin: eine Pilotstudie. *Dtsch Med Wochenschr* 2002; 127(3): 78–82
11. **Eckel F**, Schmelz R, Erdmann J, Mayr M, Lersch C: Phase II trial of a 24-hour infusion of gemcitabine in previously untreated patients with advanced pancreatic cancer. *Cancer Invest* 2003; 21(5): 690–4
12. Lersch C, Schmelz R, Erdmann J, Hollweck R, Schulte-Frohlinde E, **Eckel F**, Nader M, Schusdziarra V: Treatment of HCC with pravasin, octreotide, or gemcitabine—a critical evaluation. *Hepatogastroenterol* 2004; 51(58): 1099–103

13. von Delius S, Lersch C, Schulte-Frohlinde E, Mayr M, Schmid RM, **Eckel F**: Phase II trial of weekly 24-hour infusion of gemcitabine in patients with advanced gallbladder and biliary tract carcinoma. *BMC Cancer* 2005; 5(1): 61–66
14. **Eckel F**, von Delius S, Mayr M, Dobritz M, Fend F, Hosius C, Schleyer E, Schulte-Frohlinde E, Schmid RM, Lersch C: Pharmacokinetic and clinical phase II trial of imatinib in patients with impaired liver function and advanced hepatocellular carcinoma. *Oncology* 2005; 69(5): 363–371
15. Huber W, **Eckel F**, Hennig M, Rosenbrock H, Wacker A, Saur D, Sennefelder A, Hennico R, Schenk C, Meining A, Schmelz R, Fritsch R, Weiß W, Hamar P, Heemann U, Schmid RM: Prophylaxis of contrast-induced nephropathy in ICU-patients: Acetylcysteine, theophylline or both? A randomised study. *Radiology* 2006; 239(3): 793–804
16. von Delius S, Ayvaz MA, Wagenpfeil S, **Eckel F**, Schmid RM, Lersch C: Effect of low molecular weight heparin on survival in patients with advanced pancreatic adenocarcinoma. *Thromb Haemost* 2007; 98(2): 434–9
17. von Delius S, Lersch C, Mayr M, Stock K, Schulte-Frohlinde E, Schmid RM, **Eckel F**: Capecitabine for Treatment of Advanced Hepatocellular Carcinoma. *Hepatogastroenterol* 2007; 54(80): 2310–4
18. von Delius S, **Eckel F**, Wagenpfeil S, Mayr M, Stock K, Kullmann F, Obermeier F, Erdmann J, Schmelz R, Quasthoff S, Adelsberger H, Bredenkamp R, Schmid RM, Lersch C: Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: Final results of a randomised, controlled, multicenter phase II study. *Invest New Drugs* 2007; 25(2): 173–180
19. Schulte-Frohlinde E, Wagenpfeil S, Willis J, Lersch C, **Eckel F**, Schmid RM, Schusdziarra V: Role of meal carbohydrate content for the imbalance of plasma amino acids in patients with liver cirrhosis. *J Gastroenterol Hepatol* 2007; 22(8): 1241–8
20. **Eckel F**, Schmid RM: Chemotherapy in Advanced Biliary Tract Carcinoma: A Pooled Analysis of Clinical Trials. *Br J Cancer* 2007; 96(6): 896–902
21. Herrmann K, **Eckel F**, Schmidt S, Scheidhauer K, Krause BJ, Kleeff J, Schuster T, Wester HJ, Friess H, Schmid RM, Schwaiger M, Buck AK: In vivo characterization of proliferation for discriminating cancer from pancreatic pseudotumors. *J Nucl Med* 2008; 49(9): 1437–44
22. Huber W, Umgelter A, Reindl W, Franzen M, Schmidt C, von Delius S, Geisler F, **Eckel F**, Fritsch R, Siveke J, Henschel B, Schmid RM: Volume assessment in patients with necrotizing pancreatitis: a comparison of intrathoracic blood volume index, central venous pressure, and hematocrit, and their correlation to cardiac index and extravascular lung water index. *Crit Care Med* 2008; 36(8): 2348–54
23. Bajbouj M, Becker V, **Eckel F**, Miehle S, Pech O, Prinz C, Schmid RM, Meining A: Argon plasma coagulation of cervical heterotopic gastric mucosa as an alternative treatment for globus sensations. *Gastroenterology* 2009; 137(2): 440–4
24. Hamacher R, Diersch S, Scheibel M, **Eckel F**, Mayr M, Rad R, Bajbouj M, Schmid RM, Saur D, Schneider G: Interleukin 1 beta gene promoter SNPs are associated with risk of pancreatic cancer. *Cytokine* 2009; 46(2): 182–6
25. **Eckel F**, Herrmann K, Schmidt S, Hillerer C, Wieder HA, Krause BJ, Schuster T, Langer R, Wester HJ, Schmid RM, Schwaiger M, Buck AK: Imaging of proliferation in hepatocellular carcinoma with the in-vivo marker FLT. *J Nucl Med* 2009; 50(9): 1441–7

Reviews

1. Lersch C, Schmelz R, **Eckel F**, Erdmann J, Mayr M, Schulte-Frohlinde E, Quasthoff S, Grosskreutz J, Adelsberger H: Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer. *Clinical Colorectal Cancer* 2002; 2(1): 54–8
2. Schneider G, Siveke J, **Eckel F**, Schmid RM: Pancreatic cancer—basic and clinical aspects. *Gastroenterology* 2005; 128(6): 1606–25

3. **Eckel F**, Schmid RM: Firstline- und Secondline-Therapie des Pankreaskarzinoms. *Journal Onkologie* 2006; 4(06): 12–17
4. **Eckel F**, Schneider G, Schmid RM: Pancreatic cancer: A review of recent advances. *Expert Opin Investig Drugs* 2006; 15(11): 1395–410
5. **Eckel F**, Schneider G, Schmid RM: Pankreaskarzinom – von der Molekularbiologie zu innovativen Therapien? *Der Gastroenterologe* 2006; 1(1): 27–33
6. **Eckel F**, Schmid RM: Emerging drugs for biliary cancer. *Expert Opin Emerg Drugs* 2007; 12(4): 571–89
7. Ebert MP, Auernhammer C, Caca K, **Eckel F**, Fischbach W, Geissler M, Göke B, Greten T, Kubicka S, Lutz MP, Möhler M, Opitz O, Pavel M, Porschen R, Reinacher-Schick A, Schmiegel W, Seufferlein T, Wiedenmann B, Schmid RM: Gastrointestinale Onkologie – Therapieupdate 2008/2009. *Z Gastroenterol* 2009; 47(3): 296–306

Kasuistiken

1. **Eckel F**, Ugi I, Schmidt T, Lersch C: 44-jähriger Patient mit Kardiakarzinom und paraneoplastischer Orbitopathie. *Dtsch Med Wochenschr* 1998; 123(38): 1103–6
2. **Eckel F**, Lersch C, Erdmann J, Schmidt B, Schulte-Frohlinde E: 42-jähriger Patient mit hämolytisch-urämischem Syndrom unter Gemcitabin-Therapie eines Adenokarzinoms der Leber. *Z Gastroenterol* 2000; 38(7): 593–6
3. **Eckel F**, Lersch C, Huber W, Weiss W, Berger H, Schulte-Frohlinde E: Multimicrobial sepsis including clostridium perfringens after chemoembolization of a single liver metastasis from common bile duct cancer. *Digestion* 2000; 62(2–3): 208–12
4. **Eckel F**, Huber W, Helmberger H, Lersch C: Akutes Abdomen nach Chemotherapie und Bestrahlung eines metastasierten Sigmakarzinoms. *Tumordiagn u Ther* 2001; 22(6): 126–9
5. **Eckel F**, Huber W, Heidecke CD, Moessmer G, Berger H, Holper K, Dietrich W, Lersch C, Siewert JR: Fulminant intracardiac thrombosis associated with Budd-Chiari syndrome and inferior vena cava thrombosis. *Vasa* 2002; 31(1): 62–5
6. **Eckel F**, Huber W, Weiss W, Lersch C: Recurrent clostridium difficile colitis as a cause of recurrent severe sepsis. *Z Gastroenterol* 2002; 40(4): 255–8
7. **Eckel F**, Huber W, Moessmer G, Kock HJ, Spannagl M: Severe postoperative bleeding due to acquired haemophilia. *Eur J Anaesthesiol* 2004; 21(4): 327–9
8. von Delius S, Lersch C, Neu B, Huber W, **Eckel F**, Pitzl H, Fend F, Gaa J, Schmid RM: Squamous-cell carcinoma of the duodenum as a rare cause of upper gastrointestinal bleeding. *Endoscopy* 2006; 38(9): 956
9. von Delius S, Lersch C, Schulte-Frohlinde E, Dobritz M, Schmid RM, **Eckel F**: Hepatocellular carcinoma associated with hereditary hemochromatosis occurring in non-cirrhotic liver. *Z Gastroenterol* 2006; 44(1): 39–42

Editorial, Letter, etc.

1. Roder JD, **Eckel F**: Reconstruction after gastrectomy and quality of life. *World J Surg* 1995; 19(4): 564
2. Born P, Lippl F, Ulm K, Gerein P, Lersch C, **Eckel F**, Fischer G, Sandschin W, Dlaska U, Classen M: Faktor-XIII-Erniedrigung bei Tumorpatienten. In *Klinische Aspekte des Faktor-XIII-Mangels. Diagnostik, klinische Relevanz, klinische Forschung*, (eds.) Egbring R, Seitz R, Wozniak G. Karger: Basel, 1999 pp. 104–10
3. **Eckel F**, Lersch C, Assmann G, Schulte-Frohlinde E: Phase II trial of low-dose cyclophosphamide, leucovorin, high-dose 5-fluorouracil 24-hour continuous infusion and tamoxifen in advanced biliary tract cancer. *Ann Oncol* 2000; 11(6): 762–3
4. Huber W, Hennig M, **Eckel F**, Classen M: Kontrastmittelinduziertes Nierenversagen lässt sich durch Hämodialyse nicht verhindern. *Dtsch Med Wochenschr* 2002; 127(1–2): 45–6

5. **Eckel F**: High-dose intravenous gemolinate reduces survival time in people with inoperable pancreatic cancer. *Evidenced-based Oncology* 2002; 3(2): 87–9
6. **Eckel F**: Pankreaskarzinom. *Journal Onkologie* 2006; 4(06): 3
7. **Eckel F**, Jelic S: Biliary cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2009; 20(Suppl 4): 46–48
8. **Eckel F**, Brunner T, Jelic S: Biliary cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. *Ann Oncol* 2010; Manuskript in Vorbereitung